Production (Stage)
AIM ImmunoTech Inc.
AIM
$9.09
-$0.2665-2.85%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -64.44% | 28.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.44% | 28.57% | |||
| Cost of Revenue | 42.86% | -12.50% | |||
| Gross Profit | -84.21% | 40.74% | |||
| SG&A Expenses | -38.55% | 40.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -38.39% | 30.42% | |||
| Operating Income | 38.19% | -30.43% | |||
| Income Before Tax | 37.91% | -61.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.91% | -61.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.91% | -61.27% | |||
| EBIT | 38.19% | -30.43% | |||
| EBITDA | 38.51% | -30.84% | |||
| EPS Basic | 43.45% | -45.17% | |||
| Normalized Basic EPS | 41.13% | -30.86% | |||
| EPS Diluted | 43.45% | -45.17% | |||
| Normalized Diluted EPS | 41.13% | -30.86% | |||
| Average Basic Shares Outstanding | 9.87% | 10.99% | |||
| Average Diluted Shares Outstanding | 9.87% | 10.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||